Skip to main content
menu sluit menu
Home Home
Login
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
User tools menu
User tools menu
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
Follow IVIS
  • Twitter
  • Facebook
Support IVIS

Breadcrumb

  1. Home
  2. Library
  3. Manual of Equine Neonatal Medicine
  4. Guidelines for Drug Use in Equine Neonates
Manual of Equine Neonatal Medicine
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Comments
Print this article
Share:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter

Guidelines for Drug Use in Equine Neonates

Author(s):
Madigan J.E. and
Wilson W.D.
In: Manual of Equine Neonatal Medicine by Madigan J.E.
Updated:
FEB 06, 2017
Languages:
  • EN
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Print this article
SHARE:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter
    Read

    There are several important differences between neonates and adults in the way drugs are absorbed, distributed, metabolized and eliminated from the body [1,2]. Consequently, dosage regimens used for drugs in adult horses may not be appropriate for use in neonatal foals. With regard to drug administration, it does appear that normal equine neonates are more mature than neonates of many other species and that maturation after birth occurs more rapidly. Considerable maturation occurs in foals within the first 3 or 4 days of life and many metabolic and excretory processes are relatively mature by 1 week. Thereafter, maturation continues for many months but, in most respects, foals of >1 month of age handle drugs in a manner similar to adults.

    I. Differences between Equine Neonates and Adults Important in Drug Therapy

    1. Comparatively larger ECF volume in foals means most drugs have a larger volume of distribution. Thus, for equivalent doses, plasma concentrations of some drugs will be lower than in adults. This does not necessarily mean that tissue levels are lower or that the dose needs to be increased, since other features of distribution and elimination also influence drug concentrations.
    2. Lower plasma protein in neonates means that a greater proportion of drugs which are highly bound to plasma protein, e.g. penicillin G, sulfonamides, trimethoprim, and phenylbutazone, are present in the circulation in the unbound (active) form.
    3. The hepatic metabolic pathways (oxidation, reduction, hydrolysis and conjugation) are not fully functional at birth and are impaired further in premature foals. Thus drugs which undergo complete or partial hepatic metabolism prior to excretion may experience delayed elimination, especially during the first 3 or 4 days of life.
      Examples include chloramphenicol, trimethoprim, sulfonamides, phenobarbital, phenytoin, and theophylline. Maturation of hepatic function to near adult capacity occurs rapidly in term foals during the first 7 to 14 days of life.
    4. Renal excretion is the principal process of elimination for most polar drugs (e.g. penicillins and aminoglycosides) and the majority of drug metabolites. The renal excretory mechanisms of glomerular filtration, tubular secretion and tubular reabsorption are relatively more mature in foals than in neonates of many other species. While not fully mature at birth, renal excretory mechanisms in foals mature rapidly during the first week of life.
    5. Premature foals may have retarded maturation of their drug metabolizing and excreting mechanisms.
    6. Absorbable drugs administered orally are generally better in neonates than in adults. The resultant serum concentrations of drugs such as ampicillin, amoxicillin, trimethoprim and sulfonamides tend to be higher [3,4]. This effect is especially marked during the first 24-48 hours and can be used to advantage therapeutically. However, enhanced absorption also has the potential to enhance toxicity, particularly when clearance mechanisms are also immature.
    7. Neonates have a poorly developed blood-brain barrier. This may be useful when treating meningitis but can pose problems when selecting doses for CNS depressants (e.g. barbiturates, xylazine).
    8. Neonates have a lower content of body fat so there is less sequestration of lipid-soluble drugs. This can lead to higher plasma concentrations and more profound effects, e.g. with barbiturates.

    II. Antibiotics [5-8]

    1. Almost all systemic neonatal bacterial infections involve Gram negative (often enteric) organisms, with or without accompanying Gram positive organisms. (The opposite is usually the case in adults).
    2. Septicemic foals deteriorate rapidly. Antibiotic treatment should be started as soon as cultures have been collected and later modified, if necessary, after culture and susceptibility results are available. Front line antibiotics should have excellent activity against Gram negative bacteria and specific combination therapy is rational to broaden the spectrum. The most useful antibiotics for initiating treatment of suspected or confirmed sepsis are the aminoglycosides, e.g. amikacin or gentamicin, in combination with penicillin G, ampicillin, ticarcillin or a cephalosporin antibiotic. Depending on the susceptibility of bacterial isolates, other antibiotics which may prove useful include trimethoprim/sulfonamide, 3rdgeneration cephalosporins, or ticarcillin/clavulanic acid.
    3. Bactericidal drugs are preferred because neonates have suboptimal defense mechanisms and most infected foals have total or partial failure of passive transfer of colostral antibodies.
    4. The disease process can interfere with drug absorption, therefore parenteral routes should be used in systemically ill foals -the IV route is preferred initially.
    5. Avoid using antimicrobials which require extensive hepatic metabolism prior to excretion (e.g., chloramphenicol, erythromycin) especially in systemically ill foals with impaired liver function, and in premature foals.
    6. Use drugs which are excreted unchanged in urine, e.g. penicillins, aminoglycosides [10,11], cephalosporins or those which undergo only limited hepatic metabolism, e.g. trimethoprim/sulfonamide [9].
    1. Aminoglycosides, especially amikacin and gentamicin are very useful drugs because of their activity against Gram negative bacteria. They have been used for 14 days or more at standard doses in normally hydrated foals without apparent problems but they are potentially nephrotoxic. The following precautions should be taken:
    1. In patients with renal disease, alternative antibiotics should be used if possible. If aminoglycosides are used the dosage interval should be adjusted (lengthened) according to measured peak and trough plasma concentrations.
    2. Ensure patients are adequately hydrated (dehydration enhances toxicity).
    3. Monitor urine for evidence of tubular damage proteinuria, casts, RBC, (1+ proteinuria normal in newborn foals for 2-3 days).
    1. Current Dosing Regimens for Aminoglycosides [10-15]
    1. A once daily dosing regimen for aminoglycosides is more effective and often less nephrotoxic than the older lower dose, multiple dosing protocols in man and other species. Efficacy of aminoglycosides such as gentamicin or amikacin is concentration dependent. The magnitude of initial serum concentrations and area-under-the serum concentration vs. time curve (AUC) are more important in bacterial killing and in determining a post-antibiotic effect than is the duration that concentrations remain above the MIC of microbes. In adult horses, such a dosing regimen (6.6 mg/kg q 24 h) with gentamicin has been shown to produce significantly higher peak serum concentrations and AUC as compared to standard dosing protocols (2.2 mg/kg q 8 hr). Similar peaks and pharmacokinetics consistent with increased efficacy were determined in a study involving 21 mg/kg of amikacin administered once daily to neonatal foals for 10 days.
    2. Nephrotoxicity was not observed after a 10 day course of once daily administered gentamicin in adults and amikacin in neonatal foals. A retrospective study also showed that hospitalized neonatal foals had optimal pharmacokinetics of amikacin when administered at a dose of 2O-25 mg/kg once daily, based on therapeutic drug monitoring.
    3. Therapeutic drug monitoring (TDM) ensures dosing intervals and quantities that are both safe and effective. TDM entails measuring serum concentrations of aminoglycosides from two serum samples, one obtained one hour after administration (after the distribution phase is complete) and a second obtained before the next dosing. In the case of once daily therapy, this second sample should be obtained 4-8 hours after dosing. Peak and trough concentrations can then be obtained. Target trough concentrations are minimum target concentrations to minimize the risk for nephrotoxicity, and are ≤1 μg/ml and ≤4 μg/ml for gentamicin and amikacin, respectively. Target peak concentrations should be a minimum of >10 μg/ml and 14 μg/ml for gentamicin and amikacin, respectively.
    4. Patients on aminoglycoside therapy should be monitored for signs of nephrotoxicity, especially if hypovolemia or reduced renal perfusion is suspected. Serum concentrations of creatinine and blood urea nitrogen can be used, however, urine indices (urine specific gravity, urinalysis, fractional excretions) are more sensitive and will detect toxicity earlier.
    5. When on IV fluids: Just as therapeutic drug monitoring is important for patients with lowered volumes of distribution (dehydration, hypovolemia) to ensure safety, it is similarly important for those patients with increased volumes and clearance, such as those on intravenous fluid therapy, to ensure adequate peaks.
    6. Intraosseous therapy of aminoglycosides has been shown to closely approximate the pharmacokinetics of these drugs given intravenously, and is a viable alternative route for patients where venous access is limited [12].

    Antibiotic Doses Commonly Used in Neonatal Foals [1,2]

    Drug

    Dose

    Frequency

    Penicillin G, K

    20,000-40,000 iu/kg

    QID

    Penicillin G, Na

    20,000-40,000 iu/kg

    QID

    Penicillin G, Procaine

    22,000 iu/kg

    BID

    Ampicillin, Na

    20 (10-50) mg/kg

    TID or QID

    Ampicillin trihydrate

    20 mg/kg

    TID

    Amoxicillin trihydrate

    20-30 mg/kg

    TID or QID

    Oxacillin

    25-50 mg/kg

    TID or QID

    Amikacin sulfate

    7 mg/kg or
    10 mg/kg or
    21 mg/kg

    BID or TID
    BID
    Q24 h

    Gentamicin sulfate

    2.2 mg/kg or
    3.3 mg/kg or
    6.6 mg/kg

    BID or TID
    BID
    Q 24 h

    TMP/sulfa

    5 mg/kg

    BID or TID

    Back to Table of Contents
    Add to My Library
    Close
    Would you like to add this to your library?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    Print this article
    References

    1. Baggot JD and Short CR. Drug disposition in the neonatal animal with particular reference to the foal. Equine Vet J 16(4):364-367, 1984. - PubMed -

    ...
    Show all
    Comments (0)

    Ask the author

    0 comments
    Submit
    Close
    Would to like to further discuss this item?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    About

    How to reference this publication (Harvard system)?

    Madigan, J. E. and Wilson, W. D. (2017) “Guidelines for Drug Use in Equine Neonates”, Manual of Equine Neonatal Medicine. Available at: https://www.ivis.org/library/manual-of-equine-neonatal-medicine/guidelines-for-drug-use-equine-neonates (Accessed: 10 June 2023).

    Affiliation of the authors at the time of publication

    School of Veterinary Medicine, University of California-Davis, CA, USA.

    Author(s)

    • John Madigan

      Madigan J.E.

      Professor of Medicine and Epidemiology
      MS DVM Dipl. ACVIM ACAW
      Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California
      Read more about this author
    • David Wilson

      Wilson W.D.

      Professor Emeritus
      DVM PhD Dipl ACVIM
      Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California
      Read more about this author

    Copyright Statement

    © All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.
    Related Content

    Readers also viewed these publications

    • Journal Issue

      Veterinary Evidence - Vol 8 N°2, Apr-Jun 2023

      In: Veterinary Evidence
      JUN 07, 2023
    • Proceeding

      NO Laminitis! Virtual Conference - 2021

      By: ECIR - Equine Cushing's and Insulin Resistance Group Inc.
      MAY 02, 2023
    • Proceeding

      BEVA - Annual Congress - Liverpool, 2022

      By: British Equine Veterinary Association
      MAR 20, 2023
    • Journal Issue

      Veterinary Evidence - Vol 8 N°1, Jan-Mar 2023

      In: Veterinary Evidence
      MAR 19, 2023
    • Proceeding

      AVEF - Conférence Annuelle - Reims, 2022

      By: Association des Vétérinaires Équins Français
      MAR 03, 2023
    • Proceeding

      EEHNC - Virtual Congress - 2021

      By: European Equine Health and Nutrition Congress
      FEB 09, 2023
    • Proceeding

      SFT - Theriogenology Annual Conference - Bellevue, 2022

      By: Society for Theriogenology
      JAN 10, 2023
    • Proceeding

      ACVIM & ECEIM - Consensus Statements

      By: American College of Veterinary Internal Medicine
      NOV 11, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°2, Apr-Jun 2022

      In: Veterinary Evidence
      OCT 07, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°3, Jul-Sep 2022

      In: Veterinary Evidence
      OCT 04, 2022
    • Journal Issue

      Veterinary Practice Management Articles - Veterinary Focus

      In: Veterinary Focus
      AUG 05, 2022
    • Chapter

      Nutrition

      In: The Clinical Companion of the Donkey (2nd Edition)
      JUL 09, 2022
    • Chapter

      Pharmacology and Therapeutics

      In: The Clinical Companion of the Donkey (2nd Edition)
      JUL 03, 2022
    • Chapter

      Sedation, Anaesthesia and Analgesia

      In: The Clinical Companion of the Donkey (2nd Edition)
      JUN 05, 2022
    • Chapter

      The Geriatric Donkey

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 20, 2022
    • Chapter

      Euthanasia and the Post-Mortem Examination

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 20, 2022
    • Chapter

      Appendix 7: Example Diets: for the mature, pregnant and lactating donkey

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 2: Donkey Weight Estimator

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 1: The Clinical Examination

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 5: Monitoring your Donkey’s Quality of Life

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 6: Professional record of Assessment for Quality of Life

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 3: Body Condition Scoring

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Appendix 4: Parameters: Biochemistry and Haematology

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      The Care of the Foal

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 12, 2022
    • Chapter

      Approach to the Dull Donkey

      In: The Clinical Companion of the Donkey (2nd Edition)
      MAY 07, 2022
    • Load more
    Buy this book

    Buy this book

    The Manual of Equine Neonatal Medicine can be purchased either directly from the Live Oak Publishing or via Amazon.

    Buy this book from one of the distributors listed below
    Amazon Logo
    Amazon
    https://www.amazon.com/s?k=manual%20of%20equine%20neonatal%20medicine&crid=2M7W…
    Back To Top
    Become a member of IVIS and get access to all our resources
    Create an account
    Sign in
    Leading the way in providing veterinary information
    About IVIS
    • Mission
    • What we do
    • Who we are
    Need help?
    • Contact
    Follow IVIS
    • Twitter
    • Facebook
    International Veterinary Information Service (IVIS) is a not-for-profit organization established to provide information to veterinarians, veterinary students, technicians and animal health professionals worldwide using Internet technology.
    Support IVIS
    © 2023 International Veterinary Information Service
    • Disclaimer
    • Privacy Policy